Why Vitamin K2 (MK-7) Should Be Considered Alongside Calcium and Vitamin D in Bone Health

The Current Standard: Calcium and Vitamin D3

Patients at risk of bone loss are often prescribed Calci-D®, which combines calcium carbonate with colecalciferol (vitamin D3). This supports bone mineralisation and addresses widespread vitamin D deficiency, especially in the UK.

Yet, the standard dose of vitamin D in Calci-D®—400 IU per tablet—falls below the 800–2,000 IU daily range recommended in both UK and international guidelines for bone protection. Clinical notes recommend adding an adjunct 1,000 IU vitamin D3 daily, bringing the intake closer to the evidence-based target while remaining well below the safe upper limit of 4,000 IU (Royal Osteoporosis Society, 2024).

NHS Prescribing of Additional Vitamin D3

While 400 IU vitamin D is included in combination tablets such as Calci-D® and Adcal-D3®, many patients require more to reach protective levels.

• NHS guidance recommends 800–2,000 IU daily for people with osteopenia, osteoporosis, HIV, or other high-risk conditions.
• When combined products don’t provide enough vitamin D, doctors can prescribe colecalciferol (vitamin D3) tablets or capsules separately.
• Typical NHS-prescribed maintenance doses are 800 IU, 1,000 IU, or 2,000 IU daily.
• In deficiency, higher “loading doses” (20,000–50,000 IU weekly for a short period) may be used before switching to maintenance.

In some NHS regions, vitamin D for healthy adults is classed as a self-care item (purchased over the counter). However, for patients with osteopenia, osteoporosis, low vitamin D, HIV, chronic illness, or those on bone-active therapies, vitamin D is prescribable to ensure safety and monitoring.

Other NHS-Prescribed Alternatives to Calci-D®

Calci-D® is not the only calcium + vitamin D preparation prescribed on the NHS. Other options include:

Adcal-D3® (Calcium Carbonate + Colecalciferol)

• Chewable tablets: 600 mg calcium + 400 IU vitamin D.
• Caplets: 300 mg calcium + 200 IU vitamin D per caplet.
• Effervescent tablets: 600 mg calcium + 400 IU vitamin D (for patients with swallowing difficulties).

These are considered first-line alternatives and widely used where Calci-D® is unsuitable.

Accrete D3® (Scotland)

• Accrete D3® One-A-Day chewable tablets.
• Accrete D3® film-coated tablets (twice daily).
• Adcal D3 Dissolve® effervescent tablets for those with swallowing difficulties.

Separate Prescriptions

When combination products are not tolerated, patients may receive:

• Colecalciferol (vitamin D3) capsules or tablets at 800–2,000 IU daily.
• Emphasis on dietary calcium intake, with supplements added only if insufficient.

The Missing Link: Vitamin K2 (MK-7)

Calcium and vitamin D help supply and absorb calcium, but they do not determine where that calcium ends up. Without the action of Vitamin K2 (MK-7), calcium may deposit in arteries rather than bone, raising long-term cardiovascular risk.

Vitamin K2 (MK-7) activates two key proteins:

• Osteocalcin, which binds calcium into bone.
• Matrix Gla protein (MGP), which prevents calcium from hardening blood vessels.

For patients with osteopenia, HIV, fatty liver, hyperlipidaemia, and cardiovascular risk factors, MK-7 supplementation (90–180 µg/day) offers important protective benefits.

The Evidence Base

Randomised controlled trials and meta-analyses show that Vitamin K2 (MK-7):

• Improves bone mineral density.
• Reduces fracture risk.
• Lowers vascular calcification markers.

It is safe at daily doses of 90–180 µg and already widely available as an affordable supplement.

Safe Dosing Evidence

Calcium

• Most adults need 700–1200 mg/day, preferably from food.
• High intakes of calcium from supplements (above about 1500 mg/day) can increase the risk of side effects such as stomach pain and diarrhoea.
• Discuss supplement use with your clinician.

Vitamin D (Colecalciferol, D3)

• Public Health England: All adults should take at least 400 IU/day (10 µg) in autumn and winter.
• For people with osteopenia, osteoporosis, or other bone conditions, doctors may recommend 800–2000 IU/day.
• Safe upper limit: 4000 IU/day.
• Correction doses: 20,000–50,000 IU weekly for deficiency, then maintenance.

Vitamin K2 (MK-7)

• Effective dose range: 90–180 µg/day.
• EFSA: Safe up to 360 µg/day for adults.
• Clinical trials: Long-term use of 180 µg/day showed safety and bone benefit.
• ⚠️ Contraindication: Do not use with warfarin or vitamin K antagonist anticoagulants.

Magnesium

• RDA: 320–420 mg/day for adults (varies by sex and age).
• Upper safe limit: 350 mg/day from supplements (food magnesium is not included in this limit).
• Note: Excess supplementation may cause diarrhoea.

Omega-3 Fatty Acids (EPA + DHA)

• Effective dose: 1–2 g/day EPA+DHA for bone and cardiovascular support.
• Safe upper limit: up to 5 g/day combined EPA+DHA.
• Note: Higher doses may be prescribed for hypertriglyceridaemia under medical supervision.

Protein

Recommended intake for bone health: 1.0–1.2 g/kg/day in older adults with osteopenia/osteoporosis.Safe upper limit: Up to ~2.0 g/kg/day in healthy adults is well tolerated (higher in athletes).Distribute protein across meals for optimal muscle and bone support.

Evidence-Based Improvements to Supplementation

Research suggests several ways to optimise this strategy further:

1. Optimise Vitamin D Form and Dose: Use vitamin D3, not D2. Daily dosing (800–2000 IU) is preferred over very high bolus doses.
2. Consider Calcium Citrate Instead of Carbonate: Better absorption in some patients.
3. Ensure Magnesium Sufficiency: Magnesium is required for vitamin D activation.
4. Balance Omega-3 Fatty Acids (EPA/DHA): Anti-inflammatory effects may support bone.
5. Ensure Adequate Protein Intake: Supports bone matrix and muscle mass.
6. Individualised Monitoring: Lab checks for vitamin D and calcium are recommended.

Why Prescribing Matters

While Vitamin K2 (MK-7) supplements can be purchased over the counter, leaving patients to source them themselves risks inequality and poor monitoring. Prescribing ensures equity, safety, and consistency of care, particularly for patients already on NHS-funded calcium and vitamin D.

A Practical Path Forward

For patients with osteopenia and multiple comorbidities, a more comprehensive approach could look like this:

• Calci-D® once daily (calcium + 400 IU vitamin D) or an NHS-approved alternative (e.g., Adcal-D3®).
• Additional 1,000 IU vitamin D3 daily (to reach optimal levels).
• Vitamin K2 (MK-7) (90–180 µg daily) (to guide calcium into bone and protect arteries).

This Calcium + Vitamin D + Vitamin K2 (MK-7) combination is safe, cost-effective, and strongly supported by emerging evidence.

Conclusion

The conversation around bone health needs to evolve. While calcium and vitamin D remain essential, they are not the full story. Incorporating Vitamin K2 (MK-7) into NHS guidance could reduce fractures, protect cardiovascular health, and ensure patients receive the most effective, evidence-based care.

It is time for NICE to review the evidence and close this critical gap in osteoporosis and osteopenia management.

---

Join the Zero Jargon Health Community

• Threads
• Instagram
• Facebook

---

IMPORTANT MEDICAL DISCLAIMER

The content provided in this blog post is for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Always consult with a qualified healthcare professional or your GP before starting any new supplement regimen, particularly if you manage pre-existing conditions or take prescription medication.

---

References

1. Royal Osteoporosis Society (2024). Vitamin D and Bone Health. https://theros.org.uk/information-and-support/osteoporosis/treatment/vitamin-d-and-bone-health/
2. NHS England (2023). Guidance on calcium and vitamin D supplementation. https://primarycare.northeastlondon.icb.nhs.uk/wp-content/uploads/2024/01/Calcium-and-vitamin-D-colecalciferol-preparations-for-adults-at-risk-of-osteoporosis-guidance-NEL_12.2023.pdf
3. Right Decisions NHS Scotland (2023). Calcium and Vitamin D Formulary. https://rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/formularies/highland-formulary/endocrine-system/drugs-affecting-bone-metabolism/osteoporosis/calcium-and-vitamin-d-formulary/
4. Torbay and South Devon NHS (2023). Vitamin D Treatment Pathway. https://www.torbayandsouthdevon.nhs.uk/uploads/24008.pdf
5. Oxfordshire Joint Formulary (2024). Osteoporosis – Calcium and Vitamin D Preparations. https://www.oxfordshireformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=9&SubSectionID=A100&SubSectionRef=09.06
6. NHS Greater Glasgow and Clyde (2023). Vitamin D and Calcium Supplement Reminder. https://ggcmedicines.org.uk/blog/medicines-update/vitamin-d-calcium-and-vitamin-d-supplements-a-seasonal-reminder/
7. Knapen MH, et al. (2013). Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis International, 24(9):2499–2507. PubMed: https://pubmed.ncbi.nlm.nih.gov/23525894/
8. Vermeer C, et al. (2012). Vitamin K as a regulator of vascular calcification and bone metabolism. J Nutr Metab, 2012:635983. PubMed: https://pubmed.ncbi.nlm.nih.gov/22489217/
9. Huang ZB, et al. (2015). Does vitamin K2 supplementation improve bone mineral density and reduce fracture risk? A meta-analysis of randomized controlled trials. Osteoporosis International, 26:1175–1186. PubMed: https://pubmed.ncbi.nlm.nih.gov/25652185/
10. Cockayne S, et al. (2006). Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med, 166(12):1256–1261. PubMed: https://pubmed.ncbi.nlm.nih.gov/16801507/
11. Rønn SH, et al. (2016). Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the femoral neck in postmenopausal women. Osteoporosis International, 27:2417–2426. PubMed: https://pubmed.ncbi.nlm.nih.gov/26891879/
12. EFSA Panel on Dietetic Products, Nutrition and Allergies (2017). Scientific opinion on the safety of vitamin K2 (menaquinone-7). EFSA Journal 15(5):4780. https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2017.4780
13. Royal Osteoporosis Society (2024). Vitamin K and Bone Health. https://theros.org.uk/information-and-support/osteoporosis/treatment/vitamin-k-and-bone-health/
14. Institute of Medicine (2011). Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press. https://www.ncbi.nlm.nih.gov/books/NBK56070/
15. NICE Patient Submission (2024). Request for NICE to review Vitamin K2 (MK-7) in bone health prescribing.

Calci-D®, Adcal-D3®, and Accrete D3® are registered trademarks of their respective manufacturers. All trademarks are acknowledged.